Novavax Inc - Company Profile
Powered by 
All the sales intelligence you need on Novavax Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Novavax Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Novavax Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Novavax Inc (Novavax) is a biotechnology company that discovers, develops and commercializes vaccines for the prevention of infectious diseases. The company focuses on developing vaccines using its recombinant protein-based nanoparticle technology and proprietary Matrix-M adjuvant. Novavax's major products include its COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its pipeline products include COVID-19 prototype vaccine (NVX-CoV2373), COVID-19 updated vaccine (NVX-CoV2601), vaccines indicated for the prevention of Ebola virus, Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). The company is also developing proprietary immune stimulating saponin-based adjuvants. The company collaborates with partners such as Sanofi, Takeda Pharmaceutical Company Limited, and Serum Institute of India Pvt. Ltd. to distribute its products. It operates research and manufacturing facilities in Gaithersburg, Maryland; Uppsala, Sweden; and Bohumil, Czech Republic. Novavax is headquartered in Gaithersburg, Maryland, the US.
Headquarters
United States of America
Address
700 Quince Orchard Road, Gaithersburg, Maryland, 20878
Website
www.novavax.com
Telephone
1 240 2682000
No of Employees
749
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
NVAX (NASD)
Revenue (2024)
$1.1B
64.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
334.8%
(2024 vs 2023)
Market Cap*
$1.6B
Net Profit Margin (2024)
XYZ
242.6%
(2024 vs 2023)
* As of and is in US$
Novavax Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| ResVax - RSV F Vaccine | Novavax |
| Combination Seasonal Influenza/RSV F Vaccine | NanoFlu |
| Ebola GP Vaccine | ResVax |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In September, the company received approval for its Covid vaccine, Nuvaxovid in Japan. |
| 2025 | Contracts/Agreements | In September, the company expanded its collaboration with Sanofi to include the use of its Matrix-M adjuvant in Sanofi's pandemic influenza vaccine candidate program. |
| 2025 | Regulatory Approval | In August, the company received approval from the US FDA for Nuvaxovid in the US. |
Competitor Comparison
| Key Parameters | Novavax Inc | Johnson & Johnson | Merck & Co Inc | Pfizer Inc | AstraZeneca Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United Kingdom |
| City | Gaithersburg | New Brunswick | Rahway | New York City | Cambridge |
| State/Province | Maryland | New Jersey | New Jersey | New York | Cambridgeshire |
| No. of Employees | 749 | 138,200 | 75,000 | 75,000 | 96,100 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John C. Jacobs | Chief Executive Officer; President; Director | Executive Board | 2023 | 58 |
| Margaret G. McGlynn | Chairperson | Executive Board | 2025 | 65 |
| James P. Kelly | Chief Financial Officer; Treasurer; Executive Vice President | Senior Management | 2021 | 59 |
| Elaine O’Hara | Executive Vice President; Chief Strategy Officer | Senior Management | 2023 | 57 |
| Mark J. Casey | Executive Vice President; Secretary; Chief Legal Officer | Senior Management | 2023 | 62 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer